Six Premier Craft Beverage Equipment Suppliers Merge in $100 Million Deal to Launch First-Ever One-Stop-Shop for All Craft Beverage Needs
20.4.2023 14:30:00 EEST | Business Wire | Press release
Lotus Beverage Alliance, a collective of experienced craft beverage equipment manufacturing companies, today announced that it has officially launched as a company. Six leading American craft beverage equipment suppliers have merged in a $100 million deal to create Lotus Beverage Alliance. The combined capabilities of Lotus Beverage Alliance will enable beverage manufacturers of all sizes to access the most comprehensive array of products spanning every step of production for craft beer, wine, hard cider, spirits, cold brew coffee, ready-to-drink cocktails, kombucha, CBD/THC-infused drinks, and sake beverages.
The six merged companies, Alpha Brewing Operations, GW Kent, Twin Monkeys, Stout Tanks and Kettles, Brewmation, and Automated Extractions, are leaders in craft beverage equipment manufacturing and offer essential infrastructure and technology for diversifying the craft beverage industry. The five founders of the six companies will remain in senior leadership positions at Lotus: Matt Rennerfeldt, John Watt, Kevin Weaver, Josh Van Riper, and Randy Reichwage. John Ansbro, an industry veteran with more than 30 years of experience in equipment manufacturing, has been named Chief Executive Officer for Lotus. Ansbro has held senior executive positions at Alfa Laval, Johnson Controls, and the GEA Group.
“Lotus has everything craft beverage creators need to produce the amazing artisanal products they love, for people who love them,” said John Ansbro, CEO of Lotus Beverage Alliance. “Our team’s proven industry experience includes a deep bench of experts helping to optimize the production of handcrafted beverages for consumers to enjoy.”
Lotus Beverage Alliance brings these leading equipment makers under one roof to become the only end-to-end provider dedicated to crafting possibilities for beverage makers, from nationally-distributed beverage purveyors to the everyday craft enthusiast. Lotus Beverage Alliance produces 1,500+ top-shelf products, including turn-key brewhouse production equipment, 304 stainless steel conical fermenters, brew kettles, IBC totes, multi-capacity tanks, mash tuns, brite tanks, canning systems, automation and control systems, packaging, thermal processes and sanitation equipment, raw ingredient supply, parts, and more.
In another industry first, Lotus introduced a proprietary financing program that offers customers affordable financing options, removing cost barriers for startups and smaller beverage producers. Credit approvals typically take less than 24 hours to provide clients with maximum flexibility.
“What a bold vision to pull together such well-respected leaders of each of their respective craft beverage supplier channel segments. The result of this merger for craft beverage makers is sure to be exponential growth and continued beverage innovation,” said Banjo Bandolas, Director of Advertising and Sales at ProBrewer.com. “Lotus appears to be a first-mover by creating a one-stop-shop for craft brewers and companies moving into ‘beyond beer’ products. I look forward to seeing where it evolves.”
Beverage makers who select Lotus Beverage Alliance as their trusted equipment partner can expect:
- Responsive and expert customer service
- A one-stop-shop supply chain for all production needs
- Ready-to-ship production parts and equipment
- High-performance equipment with extended life cycles
- Seamless equipment integration with several third-party brands
- Opportunities for reduced operating costs and downtime through automation
- Greater uptimes and efficiencies in production processes
- Post-purchase technical and operations support
- Proprietary purchase financing program with typical approval in 24 hours
Lotus Beverage Alliance offers extensive support for startups and scale-ups, including:
- Brewing and Distilling
- Quick Ship Equipment and Parts
- Packaging
- Automation and Controls
- Extraction Processing
- Beverage Production Support
Following the six-way merger, the Lotus Beverage Alliance ownership structure includes the founders from all six businesses. Additionally, Lotus has implemented an employee ownership program, at no cost to the employees. Employee ownership has been extended to every single employee throughout the organization. Research has shown that broad-based employee ownership programs improve worker retention, reduce income disparity, and result in higher margins, as well as improved growth and operating efficiencies across various aspects of a business. Lotus collaborated with Ownership Works (https://ownershipworks.org/) in this employee ownership program’s creation. The Lotus merger was facilitated by Ronin Equity Partners, a New York-based investment firm with a long-term growth focus. Ronin is also an investor in Lotus.
Lotus Beverage Alliance will be an exhibitor at the Specialty Coffee Expo in Portland, Oregon, Apr. 21–23, at Booth #456; and at the Craft Brewers Conference in Nashville, Tennessee, May 7-10, 2023 at Booths #500 and #945.
About L otus Beverage Alliance:
Lotus Beverage Alliance is a collective group of experienced companies with extensive knowledge and professional insight into the craft beverage industry. The organization was formed to bring excitement and resources to craft brewing companies by providing an advanced and comprehensive product line, knowledgeable technical guidance, immediate equipment and parts availability, and an excellent customer service team. To learn more about Lotus Beverage Alliance, please visit lotusbevalliance.com. Crafting possibilities.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230420005259/en/
Contact information
For Media Inquiries, Please Contact:
Craft beer media:
Jesse P. Cutler, JP Cutler Media, 415.318.9663, jesse@jpcutlermedia.com
Wine/spirits/specialty beverage media:
Michelle Barry, Chameleon Collective
603.809.2748
LotusBeverage@chameleon.co
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 14:30:00 EEST | Press release
Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
